Adiponectin Testing Market size is expected to reach USD 5 Billion by the end of 2035, growing at a CAGR of 8% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of adiponectin testing was USD 2 Billion. The growth of the market can be attributed to the rising adoption of adipose-derived products and the growing prevalence of cardiometabolic diseases across the globe. For instance, it is observed that about 1 out of 1,000 people have some sort of metabolic disease worldwide. Additionally, the increasing awareness of people on health and early diagnostic testing is estimated to drive market growth. Further, the rising living standards of people spend on healthcare needs and necessary testing is anticipated to have a positive impact on market growth in coming years.
Adiponectin is a type of protein hormone that is responsible for the modulation of multiple metabolic processes. Common types of metabolic diseases are diabetes, cystinuria, phenylketonuria (PKU), albinism, and others. A report by The National Library of Medicine (NLM) showed that 1 in 7,000 people have cystinuria globally. Furthermore, the growing number of obese populations is also projected to hike the growth of the market over the forecast period. For instance, various academic types of research demonstrated that more than 39% of adults are overweight while around 13% of adults are obese across the globe. All these factors are projected to influence the growth of the market positively over the forecast period.
Growth Drivers
Growing Number of People Obesity Around the World - The increasing disposable income of people is estimated to show an increase in the consumption of more food. The growing preference of people towards processed, canned, fried, and baked foods are rising day by day leading to high-calorie intake. Lack of physical exercise and intake of extra calories leaves people in an obese state. The adoption of eating junk food, readymade food, and food from outside vendors where a lot of oil, spices, cheese, and other high-calorie ingredients are used. Adiponectin is at a low level in obese people. As of 2022, there are over 1 billion people around the world with obesity with over 600 adults, over 300 adolescents, and about 40 million children.
Increasing Adoption of Adipose-Derived Products - The adipose-derived stem cells are estimated to reach a value of about 3 billion by the end of 2030 from over 1 billion in 2021 globally.
Higher Prevalence of Cardio-Metabolic Diseases Across the Globe - According to the estimations, more than 30 million people in the U.S. suffer from metabolic syndromes such as diabetes and cardiovascular disease as the major cause of death.
Increasing Healthcare Expenditure for Research and Development Across the World – The national healthcare spending of the U.S. in 2021 increased by 3% with over USD 4 trillion per person.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~8% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 5 Billion |
|
Regional Scope |
|
Type (ELISA, Enzyme Immunoassay)
The global adiponectin testing market is segmented and analyzed for demand and supply by type into ELISA, enzyme immunoassay, and others, out of which, the ELISA segment is anticipated to hold the largest share in the global adiponectin testing market during the forecast period on account of its higher utilization in the monitoring of therapeutic drug level. Moreover, the significant utilization of ELISA in the examination of the antibodies in the blood is projected to propel the growth of the market over the forecast period. ELISA adiponectin test is done to determine the presence of antibodies in the patient’s body. These antibodies are produced by the patient t fight against harmful antigens such as viruses. ELISA applications are also included in the HIV, rotavirus, syphilis, Lyme disease, and pernicious anemia. The normal values for the adiponectin ELISA test were found to be around 4-26 mcg/ml which has to be the same in both male and female patients at all age groups. A specific enzyme is mixed with the sample of blood to obtain a colored result in the presence of any antigen. The rising number of people with cardiac problems and obesity is estimated to boost the market growth. According to the Centers for Disease Control and Prevention in 2020 around 697,000 people died suffering from heart disease in the United States.
End-user (Hospitals, Diagnostic Laboratories, Specialty Clinics)
The global adiponectin testing market is also segmented and analyzed for demand and supply by end-user in hospitals, diagnostic laboratories, and specialty clinics. Amongst these three segments, the hospitals segment is expected to garner a significant share. The hospitals are where people prefer to visit in the first place, especially during serious conditions such as heart disease or heart pain. The availability of multispecialty doctors and the presence of advanced equipment is a plus for hospitals which increases the market segment growth in the coming years. The growing demand for hospitals is also attributed to the growing number of cases of heart disorders, overweight, and cholesterol issues. The increasing number of people suffering from cholesterol and blockage of blood vessels is increasing with the increasing economic standards of people. It is reported that over 90 million population in the U.S. were suffering from cholesterol levels higher than 200mg/dL in the year 2022.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Product |
|
|
By End User |
|
North American Market Forecast
The North American adiponectin testing market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the rising cases of cardiometabolic diseases and a growing population with obesity. Data released by the Centers for Disease Control and Prevention demonstrated the fact that approximately 659,000 people lose their lives due to heart diseases annually solely in the United States. Furthermore, up-surged manufacturing of testing laboratories in the region is anticipated to boost the growth of the market in the region. Also, the increasing number of people suffering from being overweight, the rising population with type 2 diabetes, and other metabolic syndromes are estimated to boost the market growth. The increasing adoption of a high-calorie diet by most people with no physical activity or work is estimated to propel market growth. People prefer ready-to-eat food as it does not require much cooking time as people are busy in their work life. Rising stress, anxiety, and tension also increase blood pressure leading to cardiovascular disorders thereby increasing the market growth.
APAC Market Statistics
Furthermore, the Asia Pacific region is anticipated to represent lucrative opportunities for the growth of the market over the forecast period. The growth of the market in the region is ascribed to rising investments in healthcare R&D activities and a growing geriatric population with cardio metabolism and chronic diseases. Such factors are estimated to boost the growth of the market in the region over the forecast period.
Laboratory Corporation steps ahead to develop efficient clinical trial processes via Clinical Trial Management System (CTMS) which is referred to as a central repository.
Bio-Rad to merge its path with ADInstruments for the integration of the Bio-Rad Explorer Classroom Activities with Lt Biology, a newly updated collection of ADInstruments.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?